Home  »  Equity Investing   »  Why Moderna, Inc. (MRNA) stock is gloomy today?...

Why Moderna, Inc. (MRNA) stock is gloomy today?

Moderna, Inc. (MRNA) stock announced third quarter 2021 financial results after which it became bearish today. MRNA stock saw a downtrend of 15.86% to drop at $291.05 a share at the time of this writing. The stock was also red in the previous trade and went down by 0.78% at closing. Let’s deep dive to understand more about this stock.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Third Quarter 2021 Financial Results:

  • Moderna stock generated $5.0 billion in revenue in the third quarter of 2021, significantly higher than $157 million in the same prior-year period. Revenue for the nine months ended September 30, 2021, reached $11.3 billion compared to $232 million in the same tenure of the previous year. Commercial sales of the Covid-19 vaccine led to increased revenue in the reported period. The stock recorded 208 million and 510 million sales of its Covid-19 vaccine respectively for the three and nine months ended September 30, 2021.
  • The MRNA stock reported $722 million or 15% cost of sales in the third quarter of 2021 that also includes third-party royalties of $168 million. For nine months, MRNA stock recorded $1.7 billion, or 16% in the cost of sales including third-party royalties of $400 million.
  • MRNA stock spent $521 million in research and development expenses and $168 million in selling, general and administrative expenses in the third quarter of 2021. Previous year’s same period research and development expenses were $344 million and selling, general and administrative expenses were $48 million.
  • Moderna stock recorded a net income of $3.3 billion in the third quarter of 2021 as compared to a net loss of $233 million in the same quarter of the previous year. Net income for the first nine months of 2021 was $7.3 billion compared to a $474 million net loss for the same period of 2020.
  • Net cash from operating activities reached jumped from $763 million for the first nine months of 2020 to $10.3 billion for the first nine months of 2021. MRNA stock purchased property and equipment worth $164 million in the first nine months of 2021. By the end reported quarter, Moderna stock had $15.3 billion in cash and cash equivalents.

Covid-19 vaccine distribution:

Moderna stock has signed various agreements to deliver the Covid-19 vaccine. MRNA stock will deliver 110 million doses of Moderna Covid-19 vaccine to the Africa Union. Moreover, it will supply 116.5 million doses of the Covid-19 vaccine to Gavi, the vaccine alliance, by the second quarter of 2022. MRNA stock is looking forward to building a state-of-the-art mRNA facility in Africa that will produce 500 million doses every year at the 50-µg dose level.

Outlook of MRNA stock

Moderna stock has projected its product sales in the range of $15 billion to $18 billion for the full year 2021. MRNA stock expects 700 million to 800 million doses deliveries of its Covid-19 vaccine in the full year 2021. The cost of sales is expected to be between 16% to 17% and capital expenditures of $0.4 billion for full-year 2021.

Leave a Comment

Your email address will not be published.

Related Videos

[youtube-feed num=3 showheader=false  layout="gallery" subscribecolor="#FF0000"]

Most Popular

Related Videos

[youtube-feed num=6 showheader=false subscribecolor="#FF0000"]

Related Posts